Download pdf
The Current Status and Prospects of Yttrium-90 Microsphere Radioembolization in the Treatment of Liver Cancer
- 1 School of Faculty of Health Sciences and Sports, Macao Polytechnic University, Macao, China
* Author to whom correspondence should be addressed.
Abstract
Hepatocellular carcinoma (HCC), the world's most frequent primary liver cancer, affects millions of people. Since most patients are diagnosed with liver cancer at an advanced stage, the size of the tumor and the patient's physical condition often limit the feasibility of liver resection or liver transplantation. Therefore, many patients can only be treated with hepatic arterial chemoembolization (TACE) or sorafenib and so on. With the progress of glass and resin microspheres and the research of yttrium-90 microsphere radioembolization (Y-90 RE) technology, Y-90 RE has shown significant advantages in tumor control, tumor response, tolerance and side-effect management. Nowadays, Y90 microsphere radioembolization has become a key method in the treatment of HCC. This article reviews the mechanism, clinical application and comparison with other therapeutic methods of radioembolization with Y90 microspheres.
Keywords
Hepatocellular carcinoma, Yttrium-90, Y90 Microsphere Radioembolization
[1]. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 68(6), 394-424.
[2]. Nordenstedt, H., White, D. L., & El-Serag, H. B. (2010). The changing pattern of epidemiology in hepatocellular carcinoma. Digestive and Liver Disease, 42, S206-S214.
[3]. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 71(3), 209-249.
[4]. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 68(6), 394-424.
[5]. Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J. L., ... & Vilgrain, V. (2018). EASL clinical practice guidelines: management of hepatocellular carcinoma. Journal of hepatology, 69(1), 182-236.
[6]. Liu, P. H., Hsu, C. Y., Hsia, C. Y., Lee, Y. H., Su, C. W., Huang, Y. H., ... & Huo, T. I. (2016). Prognosis of hepatocellular carcinoma: assessment of eleven staging systems. Journal of hepatology, 64(3), 601-608.
[7]. Chen, Z., Xie, H., Hu, M., Huang, T., Hu, Y., Sang, N., & Zhao, Y. (2020). Recent progress in treatment of hepatocellular carcinoma. American journal of cancer research, 10(9), 2993.
[8]. Vogel, A., Martinelli, E., Cervantes, A., Chau, I., Daniele, B., Llovet, J. M., ... & Arnold, D. (2021). Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Annals of Oncology, 32(6), 801-805.
[9]. Kaplan, E., & Kaplan, S. (2021). Computed tomographic perfusion imaging for the prediction of response transarterial radioembolization with Yttrium 90 glass microspheres of hepatocellular carcinoma. European Review for Medical & Pharmacological Sciences, 25(1).
[10]. Kim, H. C., Choi, J. W., Lee, M., Kim, Y. J., Paeng, J. C., & Chung, J. W. (2021). Yttrium-90 radioembolization for hepatocellular carcinoma: virtual tumor absorbed dose as a predictor of complete response. Anticancer Research, 41(5), 2625-2635.
[11]. Villalobos, A., Wagstaff, W., Guo, M., Zhang, J., Bercu, Z., Whitmore, M. J., ... & Kokabi, N. (2021). Predictors of Successful Yttrium‐90 Radioembolization Bridging or Downstaging in Patients with Hepatocellular Carcinoma. Canadian Journal of Gastroenterology and Hepatology, 2021(1), 9926704.
[12]. Suh, Y. J., Lee, S., Chang, B. C., Shim, C. Y., Hong, G. R., Choi, B. W., ... & Choi, J. Y. (2019). Evaluation of early response to treatment of hepatocellular carcinoma with yttrium-90 radioembolization using quantitative computed tomography analysis. Korean journal of radiology, 20(3), 449-458.
[13]. Qadan, M., Fong, Z. V., Delman, A. M., Gabr, A., Salem, R., & Shah, S. A. (2021). Review of use of Y90 as a bridge to liver resection and transplantation in hepatocellular carcinoma. Journal of Gastrointestinal Surgery, 25, 2690-2699.
[14]. Entezari, P., Gabr, A., Salem, R., & Lewandowski, R. J. (2022). Yttrium-90 for colorectal liver metastasis-the promising role of radiation segmentectomy as an alternative local cure. International Journal of Hyperthermia, 39(1), 620-626.
[15]. Abdallah, M. A., Wongjarupong, N., Hassan, M. A., Taha, W., Abdalla, A., Bampoh, S., ... & Roberts, L. R. (2020). The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study. Expert review of gastroenterology & hepatology, 14(7), 619-629.
[16]. Lee, J. S., Choi, H. J., Kim, B. K., Park, J. Y., Ahn, S. H., Han, K. H., ... & Kim, S. U. (2020). The modified Response Evaluation Criteria in Solid Tumors (RECIST) yield a more accurate prognoses than the RECIST 1.1 in hepatocellular carcinoma treated with transarterial radioembolization. Gut and liver, 14(6), 765.
[17]. Mazzaferro, V., Sposito, C., Bhoori, S., Romito, R., Chiesa, C., Morosi, C., ... & Spreafico, C. (2013). Yttrium‐90 radioembolization for intermediate‐advanced hepatocellular carcinoma: a phase 2 study. Hepatology, 57(5), 1826-1837.
[18]. Vilgrain, V., Pereira, H., Assenat, E., Guiu, B., Ilonca, A. D., Pageaux, G. P., ... & Marthey, L. (2017). Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. The Lancet Oncology, 18(12), 1624-1636.
[19]. Lee, K. H., Sung, K. B., Lee, D. Y., Park, S. J., Kim, K. W., & Yu, J. S. (2002). Transcatheter arterial chemoembolization for hepatocellular carcinoma: anatomic and hemodynamic considerations in the hepatic artery and portal vein. Radiographics, 22(5), 1077-1091.
[20]. Coldwell, D. M., Kennedy, A. S., & Nutting, C. W. (2007). Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. International Journal of Radiation Oncology* Biology* Physics, 69(3), 800-804.
Cite this article
Zhang,Y. (2025). The Current Status and Prospects of Yttrium-90 Microsphere Radioembolization in the Treatment of Liver Cancer. Theoretical and Natural Science,74,183-188.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of ICBioMed 2024 Workshop: Computational Proteomics in Drug Discovery and Development from Medicinal Plants
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).